Angiogenesis inhibitors in gastric cancer

Figures & data

Table 1 Trials of bevacizumab in gastric cancer

Author	Agents	n	RR	PFS/TTP (months)	OS (months)
Shah et al^Citation11	Bevacizumab + docetaxel/cisplatin/5-FU	44	67%	12	16.8
Shah et al^Citation12	Bevacizumab + cisplatin/irinotecan	47	65%	8.3	12.3
Enzinger et al^Citation13	Bevacizumab + docetaxel/cisplatin/irinotecan	32	63%	NS	NS
El-Rayes et al^Citation14	Bevacizumab + docetaxel/oxaliplatin	38	42%	6.6	11.1
Ohtsu et al^Citation15	Bevacizumab + cisplatin/capecitabine	387	46%	6.7	12.2
Ohtsu et al^Citation15	Placebo + cisplatin/capecitabine	387	37%	5.3	10.1

Abbreviations: 5-FU, fluorouracil; n, number of subjects; RR, response rate; PFS, progression-free survival; TTP, time to progression; OS, overall survival; NS, not specified.

Table 2 Phase III and II studies of ramucirumab in gastric cancer

Study	Agents	Setting	Phase	n	HR		P-value OS (months)
NCT00917384 (REGARD)	Ramucirumab versus best supportive care	Metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine- containing combination therapy	III	355	0.776	0.047	5.2 (ramucirumab) versus 3.8 (placebo)
NCT01170663 (RAINBOW)	Paclitaxel ± ramucirumab	Metastatic gastric adenocarcinoma, refractory to or progressive after first-line therapy with platinum and fluoropyrimidine	III	665	0.807	0.0169	9.63 (paclitaxel + ramucirumab) versus 7.36 (paclitaxel)
NCT01246960	FOLFOX6 ± ramucirumab	Advanced adenocarcinoma of the esophagus, gastroesophageal junction or stomach	III	166 (estimated)	Study ongoing; results pending
NCT01983878	Ramucirumab	Metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients	II	33 (estimated)	Study ongoing; results pending

Abbreviations: n, number of subjects; HR, hazard ratio; OS, overall survival.

Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011;29(7):868–874.

 PubMed Web of Science ®Google Scholar

Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter Phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24(33):5201–5206.

 PubMed Web of Science ®Google Scholar

Enzinger PC, Ryan DP, Regan EM. Phase II trial of docetaxel, cisplatin, irinotecan and bevacizumab in metastatic esophagogastric cancer [abstract]. J Clin Oncol. 2008;26(15):4552.

 Web of Science ®Google Scholar

El-Rayes BF, Zalupski M, Bekai-Saab T, et al. A Phase II study of bevacizumab, oxaliplatin, and doectaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol. 2010;21(10):1999–2004.

 PubMed Web of Science ®Google Scholar

Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled Phase III study. J Clin Oncol. 2011;29(30):3968–3976.

 PubMed Web of Science ®Google Scholar